GET DAILY SIGNALSSummit Therapeutics (SMMT) Q3 Earnings Preview: Cash Runway and PDUFA Timing
Key Takeaways
- Summit Therapeutics is a clinical-stage biopharmaceutical company with no marketed product in the U.S., so third-quarter revenue is expected to remain negligible.
- Consensus estimates point to a net loss of roughly $0.28 to $0.29 per share for the third quarter ended September 30, 2026.
- The company's lead drug candidate, ivonescimab, faces a PDUFA decision from the FDA on November 14, 2026 — just days after the expected earnings report.
- Investors will focus on the company's cash position and R&D spending tied to three late-stage clinical trials.
- Final PFS data from the HARMONi-3 squamous cohort remains on track for the second half of 2026.
Why This Earnings Report Stands Out
Summit Therapeutics (SMMT) is a Miami-based biopharmaceutical company developing ivonescimab, a PD-1/VEGF bispecific antibody for cancer. Because the company has no approved product generating sales, earnings reports are driven less by revenue and more by cash runway, clinical trial progress, and regulatory milestones. This particular report carries unusual weight: it lands just before a November 14, 2026 PDUFA decision on ivonescimab for EGFR-mutated non-small cell lung cancer, making it a key checkpoint for investors tracking both the company's financial health and its path to a potential first U.S. approval. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Expect for Q3
For the third quarter ended September 30, 2026, analysts expect Summit Therapeutics to post a net loss of roughly $0.28 to $0.29 per share, with consensus revenue estimates of approximately $0.07 million — reflecting a pre-commercial business. In the year-ago quarter, the company reported a loss of about $0.31 per share, so the current consensus implies a slightly narrower loss on an adjusted basis.
Rather than top-line figures, investors will scrutinize operating expenses, particularly R&D costs supporting three late-stage ivonescimab studies. The company ended the second quarter with about $690.7 million in cash, cash equivalents, and short-term investments, and has since filed a new $380 million ATM offering facility for financing flexibility. Guidance commentary and any updates on commercial launch preparations ahead of the PDUFA date will also be closely watched.
How the Market Is Approaching This Release
Sentiment heading into this report is tied closely to binary clinical and regulatory catalysts rather than quarterly financials alone. Summit Therapeutics shares fell sharply earlier in 2026 after an interim analysis of the HARMONi-3 squamous cohort did not clear the high bar needed for an early regulatory discussion, eliminating hopes of an accelerated path. That backdrop leaves investors focused on the upcoming final PFS readout and the November PDUFA decision. Heading into earnings, expectations center on whether management reaffirms its timelines, provides clarity on cash runway, and signals progress on commercial readiness — all of which could drive near-term volatility independent of the reported loss.
Looking Ahead After the Report
Following this report, investors should watch the company's cash position and spending trajectory. With three Phase III trials underway and commercial launch preparations accelerating, R&D and operating expenses are likely to remain elevated. Management's commentary on whether the $380 million ATM facility will be used, and at what pace, will help investors gauge the company's runway.
The most important near-term catalyst is the November 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC. A favorable decision would mark a potential first U.S. approval and shift the narrative toward commercialization.
Beyond that, investors should monitor the final PFS results from the HARMONi-3 squamous cohort expected in the second half of 2026, the planned interim overall survival analysis in the first half of 2027, and data from the GSK collaboration. These milestones, rather than the quarterly loss, are likely to define the stock's direction over the coming quarters.
Integrating AI Into My Analysis Process
When preparing pieces like this, I often turn to Tickeron’s AI Screener to quickly scan comparable names in the sector and spot patterns that might otherwise take hours to identify manually. It has become a practical part of my routine for earnings-season work, especially when evaluating clinical-stage companies where fundamentals and timelines matter more than current revenue.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SMMT in upward trend: price may jump up because it broke its lower Bollinger Band on September 25, 2026
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where SMMT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 69 cases where SMMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +9.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 244 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 124 of 148 cases where SMMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 84 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
SMMT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMMT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.361) is normal, around the industry mean (3.035). P/E Ratio (-13.063) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology
Advertisement